BioSpace News Archive

Aditxt, Inc. announces the formation of a U.S.-based subsidiary Adimune, Inc. and its plans towards submission of a Clinical Trial Application for its immunotherapeutic technology drug candidate, ADI™-100.

Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), announces that CEO, Dr Anker Lundemose, will present at the upcoming J.P Morgan Healthcare Conference.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692) today announced an antibody collaboration, assignment and exclusive license agreement.

Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that it has designated SAT-3153 for development towards an IND filing.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate MB-204.

Mobius Therapeutics™, LLC, a St. Louis-based perioperative ophthalmic pharmaceutical company, has been issued US Patent #11,540,977, Injection Apparatus and Method of Use.

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:00 p.m. Pacific Standard Time.

The global 5G in healthcare market size accounted for USD 48.25billion in 2022 and is expected to attain around USD 459.71 billion by 2030 with a noteworthy CAGR of 32.55% from 2022 to 2030.

The global cell and gene therapy market size was exhibited at USD 18.61 billion in 2022 and is expected to expand around USD 93.78 billion by 2030, poised to grow at a projected CAGR of 22.41% from 2022 to 2030.

The global personalized medicine market is predicted to garner around US$ 5.7 trillion by 2030 and it is expected to reach at a registered CAGR of 11.6% over the forecast period 2022 to 2030.